The Evolution Of Crisis Response Systems: An OPEN MINDS Roundtable On Harris County's Collaborative CORE Model is starting in

Coverage Decision Memorandum for Vagus Nerve Stimulation for Treatment of Resistant Depression

May 4, 2007 Coverage Decision Memorandum for Vagus Nerve Stimulation for Treatment of Resistant Depression The Centers for Medicare and Medicaid Services (CMS) said that the Vagus nerve stimulation device manufactured by Cyberonics did not improve depression outcomes enough to merit Medicaid coverage as an alternate treatment for medication-resistant depression. Despite refusing to cover the VNS therapy device for depression treatment, CMS spokespersons said that the agency is aware that there is a need for treatment options for people who do not respond to currently available and Medicare-approved depression treatments. CMS also said that it was not convinced . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.